Biologics compared for serious infection risk

Although the risk of serious infection while taking biologics is low, some of the agents put patients at higher risk than others, a large UK study shows.

Using data from a prospective observational cohort of more than 19,000 patients with rheumatoid arthritis, researchers evaluated the incidence of serious infections, using etanercept as the reference drug.

The rate of serious infection, defined as requiring hospital admission, intravenous antibiotics or causing death, was 5.56 per 100